In a report released yesterday, Justin Walsh from B.Riley Financial reiterated a Buy rating on Vor Biopharma (VOR – Research Report), with a price target of $60.00. The company’s shares closed last Thursday at $22.27, close to its 52-week low of $18.11.
According to TipRanks.com, Walsh is a 2-star analyst with an average return of 1.5% and a 30.8% success rate. Walsh covers the Healthcare sector, focusing on stocks such as Checkpoint Therapeutics, Syndax Pharmaceuticals, and F-star Therapeutics.
Currently, the analyst consensus on Vor Biopharma is a Moderate Buy with an average price target of $57.50.
The company has a one-year high of $63.62 and a one-year low of $18.11. Currently, Vor Biopharma has an average volume of 176.7K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Vor Biopharma Inc is a clinical stage cell therapy company. It combines a novel patient engineering approach with targeted therapies to provide a solution for patients suffering from hematological malignancies.